Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y
Kyoto University Graduate School of Medicine, Japan.
Kidney Int Suppl. 1999 Jul;71:S122-5. doi: 10.1046/j.1523-1755.1999.07130.x.
The pathogenic role of hyperlipidemia in long-standing nephrotic syndrome (NS) is known to be responsible for both the progression of glomerulosclerosis and tubulointerstitial injury, especially in focal segmental glomerulosclerosis (FGS).
Aggressive lipid lowering treatment by low density lipoprotein (LDL) apheresis (LDL-A) using a dextran sulfate cellulose column to treat patients with steroid-resistant or frequently recurrent severe NS was performed first without fixing the protocol in eight patients with FGS and one with minimal change nephrotic syndrome (MCNS). The period of NS before LDL-A, number and average intervals of LDL-A until the end of the therapy, and the prognosis were investigated. Next, a multicenter study with a fixed protocol of LDL-A treatment was designed in combination with steroid therapy for treatment twice a week for three weeks and weekly for six weeks, and was performed in 17 patients with FGS. The effects on the state of NS in addition to the change of urinary eicosanoid metabolites and remission rates were evaluated.
In the preliminary study, along with a rapid improvement of hyperlipidemia, a high incidence of remission was achieved by LDL-A performed at relatively short intervals. In the multicenter study with a fixed protocol, there was a significant decrease of urinary protein (P < 0.001) and increase of serum albumin (P < 0.02) as well as a decrease of thromboxane B2 (TXB2) excretion (P < 0.05) after the treatment. Urinary excretion of TXB2 was significantly reduced after LDL-A (P < 0.05). The rate of entering into complete or incomplete remission was 71% with a relatively short duration of nephrotic-range proteinuria using the LDL-A therapy in comparison with steroid therapy alone.
The rapid improvement of hypercholesterolemia with LDL-A treatment may provide a new approach for a high rate of improvement in the degree of NS in steroid-resistant NS of FGS and MCNS.
高脂血症在长期肾病综合征(NS)中的致病作用已知与肾小球硬化和肾小管间质损伤的进展有关,尤其是在局灶节段性肾小球硬化(FGS)中。
首先对8例FGS患者和1例微小病变肾病综合征(MCNS)患者进行了积极的降脂治疗,采用硫酸葡聚糖纤维素柱进行低密度脂蛋白(LDL)吸附(LDL-A)治疗类固醇抵抗或频繁复发的严重NS患者,治疗方案未固定。研究了LDL-A治疗前NS的病程、LDL-A治疗至治疗结束的次数和平均间隔以及预后。接下来,设计了一项多中心研究,采用固定的LDL-A治疗方案,联合类固醇治疗,每周两次,共三周,然后每周一次,共六周,对17例FGS患者进行治疗。评估了除尿类花生酸代谢产物变化和缓解率外对NS状态的影响。
在初步研究中,随着高脂血症的迅速改善,通过相对短间隔进行的LDL-A治疗实现了高缓解率。在采用固定方案的多中心研究中,治疗后尿蛋白显著降低(P < 0.001),血清白蛋白升高(P < 0.02),血栓素B2(TXB2)排泄减少(P < 0.05)。LDL-A治疗后TXB2的尿排泄显著降低(P < 0.05)。与单独使用类固醇治疗相比,使用LDL-A治疗的肾病范围蛋白尿持续时间相对较短,完全或不完全缓解率为71%。
LDL-A治疗使高胆固醇血症迅速改善,可能为FGS和MCNS的类固醇抵抗性NS的NS程度的高改善率提供一种新方法。